Episodes (Page 14)
✨
Madrigal leads MASH with EU Rezdiffra approval; Viking's obesity data concerns investors.
✨
Merck KGaA aims to make digital health solutions redundant.
Emre Ozcan
✨
Top drugs in 2030 predicted; Lilly CEO seeks pricing rebalance.
✨
Tevard's tRNA platform restores full-length protein production.
Daniel Fischer
✨
Trump increases pressure on MFN pricing; pharma engages on direct sales.
Aurigene Oncology CEO
✨
Haleon aims to reach one billion more consumers by 2030.
Jo Cooper
✨
Tough biotech funding environment discussed.
Anju Ghangurde
Murali Ramachandra
✨
EU tariff deal impacts pharma.
✨
Poolbeg Pharma CEO discusses pipeline and strategy.
Jeremy Skillington
✨
Exploring ex-US markets to reduce clinical trial risk.
Renita Hite
Scott Schliebner
✨
Patient journey in rheumatoid arthritis treatment.
✨
Healthy aging requires understanding science and offering specific products.
Max Gowland
✨
Sanofi acquires Vicebio; Sarepta halts Elevidys shipments.
✨
New FDA CDER Director George Tidmarsh faces key challenges.
George Tidmarsh
✨
MoonLake Immunotherapeutics advances nanobody SLK with $500m deal.
✨
J&J Q2 results strong despite Stelara drop; Sarepta cuts jobs.
✨
Biopharma M&A activity is in a holding pattern or new normal.
Cheryl Reicin
Shawn Titcomb
✨
CBER Director cites unproven theory for overruling COVID-19 vaccine reviewers.
✨
RNA therapeutics market shows innovation in delivery and strategy.
✨
Autonomous robots in surgery discussed; Medtronic trains surgeons.
Axel Krieger
Brian Bossetta
Natasha Barrow
Shubham Singh